For those of you bold enough to have taken a position in this stock, I congratulate you! My opinion of this opportunity has not wavered at all while the stock went from basically $10 a share down to almost $6.

Last week during high volume trading days the short interest in HSDT went up by about 300,000 share bringing the total short position over 3,000,000 shares. Personally I believe these short positions have a huge problem, why? because their PoNS device works.

We have heard from independent sources from the company that the first 7 patients in Canada have had better than expected results, that could lead to some media coverage next week. The company also has their quarterly earnings call tomorrow.

If you own HSDT consider buying more at these levels, if you don’t own HSDT yet, I’d buy some ASAP. This will end up helping defray the high cost of the game of golf that we love- DISCLOSURE I personally own over 30,000 shares of HSDT, I am not retained or paid by the company, or anyone to tell you about this opportunity. I believe their PoNS device will help millions of people globally.

HSDT to Release Fourth Quarter and Fiscal Year 2018 Financial Results On March 14, 2019 – Market News Publishing

07-Feb-2019 05:35:42 AM


HELIUS MEDICAL TECHNOLOGIES INC (“HSM-T;HSDT-Q”) – To Release Fourth Quarter and Fiscal Year 2018 Financial Results – On March 14, 2019

Helius Medical Technologies, Inc. (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that fourth quarter and fiscal year 2018 financial results will be released after the market closes on Thursday, March 14.

Management will host a conference call at 4:30 p.m. Eastern Time on March 14 to discuss the results of the quarter and the year. Those who would like to participate may dial 866-393-4306 (734-385-2616 for international callers) and provide access code 8929969. A live webcast of the call will also be provided on the Events section of the Company’s investor relations website at  -events.

For those unable to participate, a replay of the call will be available for two weeks at 855-859-2056 (404-537-3406 for international callers); access code 8929969. The webcast will be archived on the Events section of the Company’s investor relations website.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first product in development is the Portable Neuromodulation Stimulator (PoNS). For more information, visit www.heliusmedical.com.

About the PoNS Device and PoNS Treatment

The Portable Neuromodulation Stimulator (PoNS) is an investigational, non-invasive, medical device in the United States, for which Helius has requested De Novo classification and 510(k) clearance from the Food and Drug Administration for the treatment of chronic balance deficit due to mild-to-moderate traumatic brain injury when combined with targeted physical therapy. PoNS is a licensed class II medical device in Canada. PoNS is currently not commercially available in the United States or the European Union. Investor Relations Contact: Westwicke Partners on behalf of Helius Medical Technologies, Inc. Mike Piccinino, CFA 443-213-0500 investorrelations@heliusmedical.com


Leave a Reply

%d bloggers like this: